Taysha Gene Therapies, Inc. - Common Stock — Balance Sheet (NASDAQ:TSHA) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 258.88 M213.96 M126.28 M172.73 M160.36 M343.32 M Total liabilities 7.58 M118.57 M125.33 M97.79 M88.84 M96.38 M Total equity 251.3 M95.38 M949 K74.94 M71.53 M246.94 M Total liabilities & shareholders' equities 258.88 M213.96 M126.28 M172.73 M160.36 M343.32 M Total debt —37.19 M37.97 M40.51 M43.94 M50.48 M Net debt —37.19 M37.97 M40.51 M43.94 M-269.66 M

News

Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript

Taysha Gene faces earnings test as Rett trial advances

Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin

Taysha doses first patient in pivotal Rett syndrome gene therapy trial

Taysha Gene Therapies stock hits 52-week high at $5.98

Biotech Stocks: Jefferies Names its 6 Top Picks for 2026

Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock

Taysha Gene Therapies stock hits 52-week high at 5.51 USD

Goldman Sachs upgrades Taysha Gene Therapies stock rating to Buy

Nagendran Sukumar sells Taysha gene therapies (TSHA) shares for $1.69m

Cantor Fitzgerald maintains Overweight rating on Taysha Gene Therapies stock

Neurogene stock price target raised to $70 from $65 at H.C. Wainwright